{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:07:50Z","timestamp":1784200070670,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jns.2011.05.041","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T09:16:51Z","timestamp":1311412611000},"page":"103-109","source":"Crossref","is-referenced-by-count":111,"title":["Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia"],"prefix":"10.1016","volume":"308","author":[{"given":"Cynthia L.","family":"Comella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jns.2011.05.041_bb0005","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.05.041_bb0010","series-title":"XEOMIN\u00ae (incobotulinumtoxinA) for injection US Prescribing Information","author":"Merz Pharmaceuticals, LLC","year":"2010"},{"issue":"5","key":"10.1016\/j.jns.2011.05.041_bb0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","article-title":"Xeomin is free from complexing proteins","volume":"54","author":"Frevert","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2011.05.041_bb0020","series-title":"Botulinum Toxin \u2014 Therapeutic Clinical Practice & Science","first-page":"389","article-title":"Properties of pharmaceutical products of botulinum neurotoxins","author":"Bigalke","year":"2008"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2011.05.041_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","article-title":"Xeomin: an innovative new botulinum toxin type A","volume":"16","author":"Frevert","year":"2009","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.jns.2011.05.041_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"J Neural Transm"},{"issue":"11","key":"10.1016\/j.jns.2011.05.041_bb0035","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2011.05.041_bb0040","article-title":"The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (Abstract 1199P)","volume":"40","author":"Consky","year":"1990","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2011.05.041_bb0045","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2011.05.041_bb0050","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2011.05.041_bb0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2011.05.041_bb0060","series-title":"Botox\u00ae (onabotulinumtoxinA) for injection US Prescribing Information","author":"Allergan, Inc.","year":"2009"},{"key":"10.1016\/j.jns.2011.05.041_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxicon.2008.04.113","article-title":"Efficacy of Dysport (botulinum toxin type A) for the treatment of cervical dystonia: a multicenter, randomized, double blind, placebo-controlled phase III study","volume":"51","author":"Truong","year":"2008","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2011.05.041_bb0070","series-title":"Data on File, Frankfurt, Germany","author":"Merz Pharmaceuticals, GmbH","year":"2010"},{"issue":"9","key":"10.1016\/j.jns.2011.05.041_bb0075","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2011.05.041_bb0080","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/IAI.65.5.1626-1630.1997","article-title":"Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms","volume":"65","author":"Chen","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.jns.2011.05.041_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/974943","article-title":"Interaction of botulinum toxin with the epithelial barrier","author":"Fujinaga","year":"2010","journal-title":"J Biomed Biotechnol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11003030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11003030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T11:08:28Z","timestamp":1592737708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X11003030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":17,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0022510X11003030"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2011.05.041","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}